Trials / Completed
CompletedNCT02719171
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic arthritis in order to select doses for further clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | risankizumab | Risankizumab administered by SC injection |
| DRUG | placebo for risankizumab | Placebo for risankizumab administered by SC injection |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-05-01
- Completion
- 2017-08-01
- First posted
- 2016-03-25
- Last updated
- 2019-05-30
- Results posted
- 2019-05-30
Source: ClinicalTrials.gov record NCT02719171. Inclusion in this directory is not an endorsement.